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Gadolinium accumulationOver the last 2 years several studies have been published regarding gadolinium deposition in brain
structures in patients with normal renal function after repeated administrations of gadolinium-based
contrast agents (GBCAs). Most of the publications are magnetic resonance imaging (MRI) based
retrospective studies, where gadolinium deposition may be indirectly measured by evaluating changes
in T1 signal intensity (SI) in brain tissue, particularly in the dentate nucleus (DN) and/or globus pallidi
(GP). The direct correlation between T1 signal changes and gadolinium deposition was validated by human
pathology studies. However, the variability of the MR equipment and parameters used across different
publications, along with the inherent limitations of MRI to assess gadolinium in human tissues should be
acknowledged when interpreting those studies. Nevertheless, MRI studies remain essential regarding
gadolinium bio-distribution knowledge. The aim of this paper is to overview current knowledge of
technical aspects of T1 signal intensity evaluation by MRI and describe confounding factors, with the
intention to achieve higher accuracy and maximize reproducibility.alho),
baidy@yahoo.com
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In the past 2 years several magnetic imaging (MRI) studies
reported high T1 signal intensity in the dentate nucleus (DN) and/or
globus pallidi (GP) in patients with normal renal function after
multiple administrations of gadolinium-based contrast agents
(GBCAs) suggesting gadolinium deposition [1–9]. The agent most
commonly implicated was gadodiamide (Omniscan®) a non-ionic
linear agent, classified according to its stability as a weak agent [10],
followed by gadopentetate dimeglumine (Magnevist®) and gadobe-
nate dimeglumine (MultiHance®), both ionic linear agents, classified
as agents with intermediate stability [10]. The more stable
macrocyclic compounds: gadoteridol (ProHance®), gadoterate
meglumine (Dotarem®), and gadobutrol (Gadavist®) have not
been associated with substantial MR imaging changes, suggesting
that the molecular structure of the GBCA, whether linear or
macrocyclic, is a crucial factor for the increase in signal intensity.
Gadolinium deposition in brain tissue and its relation to T1 signal
intensity changes was confirmed by histopathological human studies[10–13]. However, these studies found that gadolinium deposits were
present in all evaluated brain tissues (with higher concentration in DN
followed byGP) after the administration of either linear ormacrocyclic
agents, suggesting that MRI has a relative limited sensitivity to detect
gadoliniumdeposition in brain tissue. This limitation should have been
expected, as bone deposition, which has been recognized for a decade
[14], occurs at much higher levels compared to brain tissue [13], and
yet is not detected byMRI. Despite limited sensitivity, MRI remains the
best available tool to evaluate gadolinium deposition in basal ganglia,
which appears to correlate well and proportionately with the higher
deposition in bone [13].
Recent peer-reviewed papers have been published in high impact
factor radiology journals and represent similar experience reported
by experts from all over the world. Some critical methodological
issues have not been adequately standardized in a number of these
studies including the sequences used to evaluate T1 signal intensity
changes overtime, whether signal measurements between se-
quences can be correlated, the ratios used and which are optimal,
the potential effect of field strength; the reliability of excluding
previous gadolinium expositions; number of doses and volume of
doses administered, the diseases of subjects and possible differences
of retention between different disease types, and the age range of the
studied population. Thus, the aim of this review is to evaluate and
recommend imaging strategies to improve data accuracy, andlKey.com by Elsevier on June 30, 2017.
sevier Inc. All rights reserved.
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deposition in MRI-studies.
2. MRI quantification of signal changes after (GBCAs)
administration: basic principles
Onemajor limitation of MRI human studies reporting gadolinium
deposition is its retrospective nature. This unavoidable study design
explains in part the variability of the MR imaging protocols used,
which may change according to the pathology that is being studied
and among different institutions. Quantitative and qualitative
analysis have been described. Quantitative signal intensity ratios
are favored and recommended for scientific research; however, it is
difficult to apply in clinical practice. Conversely qualitative/visual
assessment analysis is applied every day to assess normal brain
structures and lesions, but is less accurate and less appropriate for
scientific studies. Regardless of the type of analysis some general
guidelines should be followed. For clarity purposes, we will address
each technical parameter and methodological aspect separately.
3. Field strength and types of T1-weighted sequences
The influence of MR field strength in quantitative and qualitative
evaluation of T1 signal intensity of DN or other brain structures is
presently unknown. It seems reasonable to assume that signal
intensity will differ between 1.5 T and 3 T, but so far no studies have
addressed this question. Therefore, we suggest analyzing data
obtained from different field strength scans separately, i.e., for a
given patient, the first (baseline) MRI and subsequent MRIs should
be performed on the same field strength for an accurate comparison.
In most of the published studies, the authors have used
T1-weighted spin echo (SE) to evaluate the DN and/or GP signal
intensity and signal changes over time. However, in some quanti-
tative [4,7,13], and qualitative [13,15] studies, different T1-weighted
sequences have been interchangeably used, including T1 SE,
T1-weighted three-dimensional magnetization-prepared rapid
gradient-echo (3D MPRAGE) [4], T1 FLASH (fast low-angle shot)
[7], and T1 fluid attenuation inversion recovery (FLAIR) [15].
Recognizing this potential confounding factor, Radbruch et al. [4]
performed a subgroup analysis to examinewhether the two different
T1-weighted sequences applied (MPRAGE and SE) had an influence
on the signal intensity ratio difference. The authors found no
statistically significant influence. In contrast, Ramalho et al. [16]
performed an intra-individual qualitative and quantitative compar-
ison between T1 SE and T1 3DMPRAGE in patients who hadmultiple
exposures to gadodiamide (Omniscan®) and found that both
sequences cannot be used interchangeably for qualitative or
quantitative analysis of signal intensity in the DN. They showed
that baseline and final examination ratios should be evaluated over
time by always using the same sequences. Also, they suggested that
qualitative analysis is better performed with MPRAGE since its
correlates better with quantitative analysis offering advantages over
SE sequences for research purposes.
It should be recognized that it is virtually impossible to exclude
some variability even when using the same imaging sequence,
especially if performed on different machines and at different
institutions. Significant variations in the sequence parameters and
technique over time are expected to provide significant variation of
the SI measurements. Nevertheless, despite these factors, variability
is much lower if the same type of sequence is used consistently,
compared with the use of completely different sequences. The aim
should be to keep the sequence parameters as consistent as possible.
One interesting possibility that requires confirmation, is a study by
Tanaka et al. [17] that examined whether noncontrast T1-weighted
images couldbe replacedwithT1-weighted images obtained followingDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisb
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intensity ratio of the DN-to-pons of the two sequences in multiple
sclerosis (MS) patients in whom accumulation of gadolinium was
previously seen. No significant difference was found between the two
sequences, suggesting that the effects of long-term accumulation of
gadolinium could be analyzed by examining T1-weighted images
acquired after injectionof gadolinium. This approach canbe veryuseful
in circumstances when the only available sequence for long-term
analysis is the post-gadolinium T1-weighted sequence.
4. Quantitative ratios measurements
Different ratios have been used for quantitative measurements
including DN-to-pons, DN-to-middle cerebellar peduncle,
DN-to-cerebellar white matter, DN-to-CSF, DN-to-corpus callosum
genu (CC), GP-to-Th, GP-to-CSF, GP-to-CC, Th-to-CC, and Caudate
nucleus-to-CC [1–9,17–20]. In a study with healthy volunteers, T1 SI
of DN, pons, GP, white matter, and gray matter were all evaluated
and normalized with CSF [21].
Up to the present time, no dedicated study has focused on
comparing these ratios in their entirety, although Radbruch et al. [4]
compared DN T1 signal intensity with that of pons, CSF, and
cerebellum. The authors found comparable results analyzing
DN-to-pons, DN-to-CSF, and DN-to-cerebellum ratios over time in
patients who received gadopentetate dimeglumine (Magnevist®) or
gadoterate meglumine (Dotarem®).
Theoretically CSF should not be used as a control structure since it
is believed that GBCAs are able to cross blood–CSF barrier. In 2001,
Rai and Hogg [22] reported two dialysis-dependent patients with
end-stage renal diseasewho showed increased signal intensity in the
subarachnoid space on T1-weighted and FLAIR images after contrast
enhanced MRI studies suggesting CSF gadolinium diffusion. Excre-
tion of gadolinium into the CSF was proven in one case by mass
spectrometry. Later, two case reports of presumed gadolinium
induced encephalopathy with CSF T1 hyperintensity were published
by Maramattom et al. [23] and Hui et al. [24]. All described studies
reported patients with renal impairment. Recently, an animal study
by Jost et al. [25] showed enhanced signal intensity of CSF spaces in
the post-contrast FLAIR images of all animals receiving either linear
(gadodiamide (Omniscan®), gadopentetate dimeglumine (Magne-
vist®), and gadobenate dimeglumine (MultiHance®)) or macrocyclic
(gadobutrol (Gadavist®) and gadoterate meglumine (Dotarem®)
GBCAs, but not with saline (control group) [25] suggesting that
either linear or macrocyclic GBCAs are able to pass the blood–CSF
barrier in healthy rats to a certain, not yet quantified, extent. How
gadolinium can enter brain with an intact blood–brain barrier is not
yet known. One possible pathway for gadolinium entering the brain
might be passage of GBCAs directly from blood into the cerebrospinal
fluid (CSF). Recently, Cao et al. [26] reported on the renal function
effect on gadolinium-related signal increase on unenhanced T1-MRI,
and found a trend toward increased choroid plexus signal intensity
after GBCA exposure, which also supports this hypothesis.
At this point, the consensus of experts is that DN and GP are the
main locations for gadolinium deposition in brain tissue and both
represent the preferred structures for T1 signal evaluation on MRI
studies, particularly the DN. However, it is still uncertain what is the
best structure to normalize these measurements, or if any is
necessary. Further studies are needed to address this.
Tedechi et al. [27] recently described a different MRI approach
that could obviate this limitation. The authors evaluated changes on
T1 and T2* relaxometry of DNwith respect to the number of previous
administrations of GBCAs in relapsing–remitting multiple sclerosis
(RR-MS) patients. They found that the number of previous GBCA
administrations correlated with R1 relaxation rates of DN, while R2*
values remain unaffected, suggesting that T1-shortening in theseoa Central from ClinicalKey.com by Elsevier on June 30, 2017.
n. Copyright ©2017. Elsevier Inc. All rights reserved.
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administered. In fact, while standard qualitative or quantitative
analysis have variations between subjects, time-points, and imaging
centers; the measurement of relaxation rates can offer a more
consistent and reliable tissue characterization, as they are intrinsi-
cally related to tissue microstructure and are not affected by
variations in the signal intensity of images or by acquisition factors
(e.g., variable RF homogeneity and coil sensitivity profile) [27–29].
MR relaxometry likely provides accurate and reproducible quanti-
tative information of gadolinium accumulation in DN; however, it
requires specific gradient echo sequences in development that are
not at present available on standard MR systems, and hence are not
performed as part of the brain MRI protocol.
5. GBCA related concerns
Essentially all reported studies describe the number of GBCA
administrations in order to evaluate the increased T1 signal over
time. Some authors suggested that 6 or more contrast enhanced MRI
were needed to evaluate T1 signal changes over time [1,2], while
others evaluate the effect of only one high dose GBCA [21]. Provided
that the number of doses were all accounted for, including brain and
other contrast enhancedMRI, the critical factor is that only one GBCA
should be evaluated for each patient to determine the potential for
deposition of each agent.
It is accepted, that neural gadolinium deposition is more
associated with multiple administrations of the less stable GBCAs,
but the effect of these agents on subsequent more stable GBCA
administrations is undetermined. Ramalho et al. [30] evaluated the
impact of previous administration of gadodiamide (Omniscan®) and
neural tissue gadolinium deposition in patients who received
gadobenate dimeglumine (MultiHance®). Their findings suggested
a carry over effect of prior gadodiamide in gadolinium deposition
from subsequent gadobenate dimeglumine administration. In clin-
ical practice, patients may undergo MRI with different gadolinium
chelates for a variety of reasons, including imaging studies
performed at different facilities, and change in MRI contrast agents
used at the same institution (often reflecting a shift from less stable
GBCAs to more stable GBCAs). Based on these findings, we suggest
separate subgroup analysis of patients who have received only one
agent, from patients with a known history of different GBCAs
administrations, when evaluating specific gadolinium deposition
related to any specific GBCA, as multiple agents likely have additive
effects even if the current agent is macrocyclic.
6. Population variability
Population demographics and diagnosis vary among studies.
Some critical inclusion and exclusion criteria have been used to
define the investigated patient populations. First, patients with brain
lesions in the deep cerebellar nuclei unrelated to GBCA administra-
tion were excluded from analysis. In addition, patient populations
were controlled for pre-existing diseases that are known to affect SI
in the dentate nucleus or globus pallidus such as Langerhans cell
histiocytosis and multiple sclerosis. T1 W hyperintensity in the GP
has been linked to many other conditions including Wilson disease,
hepatic dysfunction, Rendu–Osler–Weber disease, manganese tox-
icity, total parenteral nutrition, hemodialysis, and neurofibromatosis
type 1 (31); which were also exclusion criteria adopted for nearly all
published studies.
It is also critical that studies regarding the effect of GBCA
administration in the brain take into account any potential
abnormalities in kidney function. Cao et al. [26] recently demon-
strated that the dentate T1 signal increase occurring in hemodialysis
patients was significantly higher compared with that of controlDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa 
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the longer exposure to GBCAs, due to longer dwell time, leads to a
greater effect on the DN in renal failure patients. Fortunately, all
published studies either used abnormal kidney function as an
exclusionary factor in their analysis or conducted careful controlled
for kidney function to ensure that any gadolinium deposition in the
brain was not caused by deficient clearance of GBCAs by the kidneys
[31]. Additionally, as a general guideline, we recommend to evaluate
and compare groups of patients with similar diagnosis, since at this
point, it is not clear what the contribution is of the underlying
pathologic process on gadolinium retention and deposition.
Regarding age, pediatric patients should be treated as a distinct
group for analysis, and one of particular concern. Brain development
begins early in fetal life and continues well into adolescence with
prefrontal, posterior parietal, and other high-order association areas
being the last areas to undergo myelination [32]. There is a dramatic
proliferation of synapses in the prefrontal cortex during early and
mid-childhood, reaching numbers that exceed adult levels by two-
or three-fold during puberty, which is then followed by a plateau
phase with subsequent elimination and reorganization of prefrontal
synaptic connections during adolescence [32]. This time period is a
critical period of development and has been considered particularly
vulnerable to toxin exposure [19,33]; and the potential for
gadolinium retention and incorporation in neural tissue in this
period is unknown. High T1 SI related to the number of GBCAs
administration has been reported in different pediatric studies
[18–20] after administration of linear GBCAs, but how this compares
to the MRI signal change in adults is still unknown.
7. MRI limitations
As stated above, MRI does not detect all the gadolinium deposits
present in human tissues following repeated administration of GBCA.
To date, bone deposition, which is likely the largest repository for
gadolinium, is not demonstrable with MRI, and only the DN and GP
exhibit MR visible deposition in the brain despite the gadolinium
presence in essentially all brain tissue. This limitation may result
from low sensitivity to lower gadolinium concentration, but it could
also be explained by the presence of gadolinium of unknown
composition and environment, or both.
It is currently considered that insoluble gadolinium salts, such as
phosphate, bicarbonate, and hydroxide, or soluble protein-bound
gadolinium should not have a known effect on T1 shortening. As
such, MR imaging significantly underestimates how much gadolin-
ium may be retained in human tissues where it is identified on MRI,
and is largely invisible in most tissues where it is present [34].
Gadolinium tissue measurements are also influenced by many
factors. Preparation of brain tissue may remove the water-soluble
contrast agent, leaving only gadolinium bound to substances other
than the chelate, and this may lead to underestimation of any
accumulation. Also, there is certainly a lower threshold level of
gadolinium where hyperintensity can no longer be seen on MR
images, but gadolinium bound to something, unlikely the chelate,
can still be measured [35]. Inductively coupled plasma mass
spectrometry (ICP-MS) is also a destructive technique in which the
tissue sample is incinerated. This means that it is unable to detect the
gadolinium species present (chelated, unchelated, and what unche-
lated may be bound to). Additionally, some tissues (notably bone)
are difficult to process.
8. Summary
In most MRI studies evaluating potential gadolinium deposition
in brain tissue, researchers evaluated the SI ratios between the DN
and GP compared to control regions, usually the pons and thalamus,Central from ClinicalKey.com by Elsevier on June 30, 2017.
opyright ©2017. Elsevier Inc. All rights reserved.
1358 J. Ramalho et al. / Magnetic Resonance Imaging 34 (2016) 1355–1358respectively. Retrospective in nature, the analyses were performed
on whichever T1-weighted MRI sequences that were performed at
each institution including T1 SE, 3D MPRAGE, FLAIR, and FLASH;
which account for an undesirable variability among the results. The
amount and type of GBCA used in each clinical population varied; as
did the age and clinical diagnosis of the patients included in each
study. Accounting for all these variables is advisable to design future
MRI-based studies in order to reach conclusions that are more
reliable and reproducible. It is prudent to keep the MR field strength
constant and the T1 weighed sequence used for each patient. T1 DN-
and GP-SI changes should be favored, while CSF should probably be
avoided as a normalizer structure. New approaches for T1 SI
evaluation may be used in prospective future studies. The GBCAs
should be evaluated individually, and previous administration of
other GBCAs should be avoided. Patients should be grouped by age,
either pediatric or adults, and by diagnosis. Nevertheless, even
controlling for all possible methodological variables, it is clear that
with currently available MR techniques, the great majority of
deposited gadolinium remains not detectable on MRI.
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